文献速递其他结缔组织病

阿巴西普治疗难治性幼年皮肌炎后疾病活动度改善

Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
PubMed 文献 · Arthritis Rheumatol · 2023-06-07

这项开放标签24周研究纳入10例≥7岁、疾病活动中度的难治性幼年皮肌炎患者,评估皮下注射阿巴西普的安全性和疗效。主要终点IMACS的DOI在12周有5例、24周有9例达到,糖皮质激素日剂量和MRI肌肉水肿评分较基线下降,作者认为阿巴西普可能对治疗难治性幼年皮肌炎患者有益。

要点

  • 24周时9例达到IMACS的DOI,其中2016年ACR/EULAR标准评估为微小改善2例、中度改善4例、重大改善3例。
  • 日糖皮质激素剂量从基线均值16.7 mg降至24周10.2 mg(P=0.002)。
  • MRI肌肉水肿评分从基线均值5.3降至24周2.3(P=0.01),观察到11例次2级或3级治疗中出现的不良事件。

核心结论

  • 这项开放标签研究显示,阿巴西普可能对治疗难治性幼年皮肌炎患者有益。

研究设计与样本

  • 开放标签、24周研究,纳入10例≥7岁、疾病活动中度的难治性幼年皮肌炎患者,评估皮下注射阿巴西普的安全性和患者治疗反应。
  • 主要终点为国际肌炎评估和临床研究(IMACS)组定义的改善(DOI);次要终点包括安全性、IMACS组和儿科风湿病国际试验组织核心活动指标集的变化,以及基于美国风湿病学会(ACR)/EULAR幼年皮肌炎应答标准的疾病活动度改善。
  • 放射科医师对参与者数据设盲,评估患者大腿肌肉的磁共振图像(MRI);采用NanoString检测全血RNA样本的干扰素(IFN)调节基因评分,采用Luminex检测细胞因子。

主要发现

  • 12周时5例患者达到DOI,24周时9例患者达到DOI;采用IMACS组核心活动指标集评估时,按2016年ACR/EULAR幼年皮肌炎应答标准,这9例中包括微小改善2例、中度改善4例、重大改善3例。
  • 除肌肉酶外,所有核心活动指标集在12周和24周均较基线改善。
  • 日糖皮质激素剂量从基线均值16.7 mg降至24周10.2 mg(P=0.002)。
  • MRI肌肉水肿评分从基线均值5.3降至24周2.3(P=0.01)。
  • 6例患者24周时IFN调节基因评分和半乳糖凝集素-9表达呈下降趋势;IFN调节基因评分及干扰素-γ诱导蛋白10kDa、半乳糖凝集素-9和白细胞介素-2水平的下降与疾病活动度和MRI肌肉水肿的改善相关。

关键数值与推荐

  • 主要终点为IMACS组DOI;24周时10例中9例达到DOI。
  • 按2016年ACR/EULAR幼年皮肌炎应答标准(采用IMACS组核心活动指标集评估),24周达到DOI的9例中微小改善2例、中度改善4例、重大改善3例。
  • 日糖皮质激素剂量基线均值16.7 mg vs 24周10.2 mg(P=0.002)。
  • MRI肌肉水肿评分基线均值5.3 vs 24周2.3(P=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This open-label, 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (DM). METHODS: Ten patients ≥7 years of age with moderate disease activity were enrolled in a 24-week study to examine the safety of subcutaneous abatacept and patient responses to the treatment. The primary endpoint was the International Myositis Assessment and Clinical Studies (IMACS) group Definition Of Improvement (DOI). Secondary endpoints included safety, changes in the core set activity measures (CSMs) of the IMACS group and the Pediatric Rheumatology International Trials Organization, and improvements in disease activity based on the American College of Rheumatology (ACR)/EULAR response criteria for juvenile DM. Radiologists blinded with regard to participant data assessed magnetic resonance images (MRIs) of patient thigh muscles. Interferon (IFN)-regulated gene score was performed on whole-blood RNA samples using a NanoString assay, and cytokines were assessed using a Luminex assay. RESULTS: Five patients achieved DOI at week 12, and 9 patients achieved DOI at week 24, including 2 patients with minimal, 4 patients with moderate, and 3 patients with major improvement by the 2016 ACR/EULAR response criteria for juvenile DM when patients were assessed using the CSMs of the IMACS Group. Improvements from baseline were seen in all CSMs at weeks 12 and 24, except in muscle enzymes. Daily glucocorticoid doses decreased from a mean of 16.7 mg at baseline to 10.2 mg at week 24 (P = 0.002). Average MRI muscle edema scores decreased from a mean baseline score of 5.3 to 2.3 at week 24 (P = 0.01). Six patients had down-trending IFN-regulated gene scores and galectin-9 expression at week 24. Decreases in IFN-regulated gene scores and in levels of interferon-γ-inducible protein 10kDa, galectin-9, and interleukin-2 correlated with improvements in disease activity and in muscle edema shown on MRI. Eleven grade 2 or 3 treatment-emergent adverse events were observed. CONCLUSION: This open-label study demonstrated that abatacept may be beneficial for patients with treatment-refractory juvenile DM.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Curiel RV, Nguyen W, Mamyrova G, et al. Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy. Arthritis Rheumatol. 2023. PMID: 36657109. doi:10.1002/art.42450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。